Warning: The NCBI web site requires JavaScript to function. more...
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.
Mayer EL, Carey LA, Burstein HJ.
Breast Cancer Res. 2007;9(5):110.
Related citations
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B, Burtness BA.
Cancer J. 2006 May-Jun;12(3):212-21.
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY.
Cancer. 2008 Jan 1;112(1):17-26. Erratum in: Cancer. 2008 Apr 1;112(7):1642. Feig, Byon [corrected to Feig, Byron].
Breast cancer, neoadjuvant chemotherapy and residual disease.
Chávez-MacGregor M, González-Angulo AM.
Clin Transl Oncol. 2010 Jul;12(7):461-7. Review.
Docetaxel as adjuvant and neoadjuvant treatment for patients with breast cancer.
Heys SD, Sarkar T, Hutcheon AW.
Expert Opin Pharmacother. 2004 Oct;5(10):2147-57. Review.
Neoadjuvant chemotherapy for locally advanced breast cancer.
Specht J, Gralow JR.
Semin Radiat Oncol. 2009 Oct;19(4):222-8. Review.
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE.
Breast Cancer Res. 2008;10(3):R45. Epub 2008 May 12.
Neoadjuvant chemotherapy for operable breast cancer.
Green M, Hortobagyi GN.
Oncology (Williston Park). 2002 Jul;16(7):871-84, 889; discussion 889-90, 892-4, 897-8. Review.
Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.
Nakabayashi M, Oh WK.
Curr Treat Options Oncol. 2004 Oct;5(5):349-55. Review.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.
J Clin Oncol. 2008 Mar 10;26(8):1275-81. Epub 2008 Feb 4.
Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA.
Cancer. 2009 Apr 15;115(8):1605-12.
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L.
J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4.
[New combination chemotherapy regimens in the primary treatment of operable breast cancer].
Conti F, Sergi D, Foggi P, Abbate MI, Lopez M.
Clin Ter. 2007 Jan-Feb;158(1):55-75. Review. Italian.
Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed.
van Riet YE, Maaskant AJ, Creemers GJ, van Warmerdam LJ, Jansen FH, van de Velde CJ, Rutten HJ, Nieuwenhuijzen GA.
Eur J Surg Oncol. 2010 Feb;36(2):164-9. Epub 2009 Nov 1.
Primary systemic chemotherapy for inflammatory breast cancer.
Sinclair S, Swain SM.
Cancer. 2010 Jun 1;116(11 Suppl):2821-8. Review.
Staging of breast cancer in the neoadjuvant setting.
Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK.
Cancer Res. 2008 Aug 15;68(16):6477-81. Review.
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
BMC Cancer. 2007 Nov 1;7:203.
Primary chemotherapy for breast cancer: the evidence and the future.
Mano MS, Awada A.
Ann Oncol. 2004 Aug;15(8):1161-71. Review.
Preoperative systemic chemotherapy and pathologic assessment of response.
Pusztai L.
Pathol Oncol Res. 2008 Jun;14(2):169-71. Epub 2008 Jun 13.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on